Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV000411224 | SCV001443316 | likely pathogenic | Glycogen storage disease, type II | 2023-03-10 | reviewed by expert panel | curation | The NM_000152.5:c.393del (p.Ser132AlafsTer10) variant in GAA is a frameshift variant predicted to cause a premature stop codon, leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). The variant is absent in gnomAD v2.1.1. (PM2_Supporting). To our knowledge, this variant has not been reported in the literature in individuals with Pompe disease, and results of experimental studies are not available. There is a ClinVar entry for this variant (Variation ID: 371580). The classification of this variant has been upgraded from Variant of Uncertain Significance to Likely Pathogenic based on the recommendations of the ClinGen Sequence Variant Interpretation Working Group, that a variant meeting PVS1 and PM2_Supporting is classified as Likely Pathogenic (https://clinicalgenome.org/site/assets/files/5182/pm2_-_svi_recommendation_-_approved_sept2020.pdf ). In summary, this variant meets the criteria to be classified as Likely Pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen Lysosomal Diseases VCEP (Specifications Version 2.0): PVS1, PM2_Supporting. (Classification approved by the ClinGen Lysosomal Diseases VCEP, March 10, 2023). |
Counsyl | RCV000411224 | SCV000487196 | likely pathogenic | Glycogen storage disease, type II | 2016-10-25 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000411224 | SCV005653175 | likely pathogenic | Glycogen storage disease, type II | 2024-04-18 | criteria provided, single submitter | clinical testing |